In total, there is growing data supporting the notion that FLT3 inhibition may have salutatory off-target effects on the donor graft which enhances the GVL effect, and in fact may become relevant as modulators of Chimeric Antigen Receptor (CAR) T cell therapies targeting FLT3 mutated AML (118, 119). This evidence concerns the gene FLT3 and acute myeloid leukemia.